The Endocannabinoid System as a Therapeutic Target in Diabetic Peripheral Neuropathic Pain
Open Access
- 1 April 2022
- journal article
- review article
- Published by Medknow in Journal of Microscopy and Ultrastructure
- Vol. 10 (2) , 47-54
Abstract
Diabetic peripheral neuropathy (DPN) is characterized by progressive loss of peripheral nerves, which causes numbness, weakness, and severe pain. The medications available currently provide only modest relief from the pain of DPN and are associated with various side effects, which has generated an enormous demand for research on new therapeutic approaches. Dysregulation of the endocannabinoid system has been reported in DPN. Cannabinoid-based medications have gained increasing attention as a potential therapy to alleviate DPN pain. Endocannabinoids and cannabinoids’ actions are mediated primarily by cannabinoid receptor 1 (CB1R) and cannabinoid receptor 2 (CB2R). Cannabinoids that activate CB1R have demonstrated a profound antinociceptive effect, although CB1R is associated with undesirable psychoactive effects. Peripherally restricted CB1R agonists help overcome this problem; however, adverse metabolic and cardiovascular effects limit its therapeutic use. In contrast, CB1R antagonists, selective CB2R agonists, and endocannabinoid metabolizing enzymes inhibitors alleviate DPN pain effectively with minimal side effects. This article provides a concise overview of the preclinical and clinical studies that have tested the therapeutic potential of targeting the endocannabinoid system to treat painful DPN.Keywords
This publication has 98 references indexed in Scilit:
- Prevention of Paclitaxel-Induced Neuropathy Through Activation of the Central Cannabinoid Type 2 Receptor SystemAnesthesia & Analgesia, 2012
- TRPV1 activation by endogenous anandamide triggers postsynaptic long-term depression in dentate gyrusNature Neuroscience, 2010
- Central and peripheral sites of action for CB2 receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in ratsBritish Journal of Pharmacology, 2010
- Moving towards Supraspinal TRPV1 Receptors for Chronic Pain ReliefMolecular Pain, 2010
- Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the BedsideNeurotherapeutics, 2009
- Minocycline Treatment Inhibits Microglial Activation and Alters Spinal Levels of Endocannabinoids in a Rat Model of Neuropathic PainMolecular Pain, 2009
- Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory painBritish Journal of Pharmacology, 2007
- Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptorsNature Neuroscience, 2007
- Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic painPain, 2006
- The Endocannabinoid System as an Emerging Target of PharmacotherapyPharmacological Reviews, 2006